{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:19:26Z","timestamp":1782296366567,"version":"3.54.5"},"reference-count":50,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T00:00:00Z","timestamp":1522368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to investigate the utilization of antiepileptic drugs (<jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s) in children and adolescents with epilepsy and other diagnoses in a nationwide population between 2007 and 2014. Data on dispensed prescriptions of <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s were collected from the Swedish Prescribed Drug Register and linked to diagnosis data from the National Patient Register covering all in\u2010 and outpatient consultations from Swedish hospitals. Children aged 0\u201317 years who had received at least one prescription for <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s were selected. We calculated proportions of patients stratified by indication, sex and type of <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>. A total of 18,131 patients (mean age 9.5 years, 50% boys) were initiated on <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content> treatment between January 2007 and December 2014. Epilepsy was the most frequent diagnosis (46%) recorded within the year prior to the first <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content> dispensing. Psychiatric and pain diagnoses were more common in girls (sex distribution 70\/30 and 59\/41, respectively). In epilepsy, the most frequently initiated <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content> was valproic acid in boys and lamotrigine in girls. Lamotrigine was the most frequently initiated drug in psychiatry, in both boys and girls. This nationwide study provides new knowledge on <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content> use in children and adolescents. The use of <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s during the study period was mainly restricted to epilepsy, and the individual <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s used seems to be in accordance with approved indications. However, the use of <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content> on non\u2010epilepsy diagnoses, especially pain disorders, raises concerns.<\/jats:p>","DOI":"10.1111\/bcpt.12981","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T09:02:41Z","timestamp":1518253361000},"page":"94-100","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Utilization of Antiepileptic Medicines in Swedish Children and Adolescents with Different Diagnoses"],"prefix":"10.1111","volume":"123","author":[{"given":"Linn\u00e9a","family":"Karlsson Lind","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Education S\u00f6dersjukhuset Karolinska Institutet Stockholm Sweden"},{"name":"The Health and Medical Care Administration Stockholm County Council Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Wide","sequence":"additional","affiliation":[{"name":"Department of Pediatrics CLINTEC Karolinska Institutet Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Wettermark","sequence":"additional","affiliation":[{"name":"The Health and Medical Care Administration Stockholm County Council Stockholm Sweden"},{"name":"Centre for Pharmacoepidemiology (CPE) Department of Medicine Clinical Epidemiology Unit Solna Karolinska Institutet Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"von Euler","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education S\u00f6dersjukhuset Karolinska Institutet Stockholm Sweden"},{"name":"Division of Clinical Pharmacology Karolinska University Hospital Solna Stockholm Sweden"},{"name":"Karolinska Institutet Stroke Research Network at S\u00f6dersjukhuset Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200822010-00003"},{"key":"e_1_2_9_3_1","unstructured":"European Medicines Agency (EMA).www.ema.europea.eu."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu038"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.160"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.08.013"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2005.08.017"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0072-9752(10)97001-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0480-z"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2011.05.003"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2006.00639.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.01970.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.07.005"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.03.002"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0139-z"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2011.02223.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02331.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2012.02.019"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02842.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12776"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-009-9350-y"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"e_1_2_9_23_1","unstructured":"Statistics Sweden[database on the Internet].www.scb.se"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2195"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108970"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.10.021"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2008.04.022"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70323-X"},{"key":"e_1_2_9_30_1","unstructured":"European Medicines Agency.Press release: CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls. 2014 [updated 2014].http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2014\/11\/news_detail_002220.jsp&mid=WC0b01ac058004d5c1(last accessed on 7 October 2016)."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31866-4"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70103-5"},{"key":"e_1_2_9_33_1","unstructured":"Medical Products Agency Sweden.Pharmacological treatment of epilepsy \u2010 new recommendation.2011[updated 2011].https:\/\/lakemedelsverket.se\/upload\/halso-och-sjukvard\/behandlingsrekommendationer\/2011_02_02_Rek%20Eilepsi-webb.pdf(in Swedish) (last accessed on 4 July 2016)."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198510103131503"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S130269"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-52891-9.00073-7"},{"issue":"12","key":"e_1_2_9_37_1","first-page":"CD011412","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta\u2010analysis of individual participant data","author":"Nevitt SJ","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_38_1","unstructured":"European Medicines Agency (EMA).Committee for Medicinal Products for Human Use (CHMP) \u2010 May 2011 plenary meeting monthly report 2011 [updated 2011].http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Committee_meeting_report\/2011\/05\/WC500106874.pdf(last accessed on January 2017)."},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.048504"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2009.00121.x"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2013.0121"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109102919"},{"key":"e_1_2_9_43_1","unstructured":"European Medicines Agency.Amendments to be included in sections of the summary of product characteristics for valproic acid\/valproate containing medicinal products as relevant. 2010 [updated 2010].http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/valproate_31\/WC500105844.pdf(last accessed on 1 March 2017)."},{"key":"e_1_2_9_44_1","unstructured":"Medical Products Agency Sweden.Neuroleptics in certain child psychiatric conditions in children and adolescents \u2010 treatment recommendation. 2016 [updated 2016].https:\/\/lakemedelsverket.se\/upload\/halso-och-sjukvard\/behandlingsrekommendationer\/Neuroleptika_vid_vissa_barnpsykiatriska_tillstand_behandlingsrekommendation.pdf(in Swedish) (last accessed on 20 September 2017)."},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.23841"},{"key":"e_1_2_9_46_1","unstructured":"Medical Products Agency Sweden.Drug treatment of long\u2010term pain in children and adults \u2010 treatment recommendation.2017[updated 2017].https:\/\/lakemedelsverket.se\/upload\/halso-och-sjukvard\/behandlingsrekommendationer\/Information_fran_lakemedelsverket_nr_3_2017_behandlingsrekommendation.pdf(last accessed on 20 September 2017)."},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2028-y"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2013.508"},{"key":"e_1_2_9_50_1","unstructured":"Food and Drug Administration (FDA).FDA approves Topamax for migraine prevention in adolescents.https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm391026.htm(last accessed on 24 February 2017)."},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118949740"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.12981","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.12981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:10:02Z","timestamp":1695478202000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.12981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,30]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/bcpt.12981"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.12981","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,30]]},"assertion":[{"value":"2017-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}